Analyst Price Targets — ARDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2026 7:10 pm | Roanna Ruiz | Williams Trading | $17.00 | $5.66 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Ardelyx, Inc (ARDX) following conference |
| February 20, 2026 11:07 am | — | H.C. Wainwright | $18.00 | $6.74 | TheFly | Ardelyx price target raised to $18 from $10 at H.C. Wainwright |
| January 27, 2026 11:23 am | — | Jefferies | $15.00 | $7.80 | TheFly | Ardelyx price target raised to $15 from $8 at Jefferies |
| January 9, 2026 10:59 am | Julian Harrison | BTIG | $17.00 | $7.00 | TheFly | Ardelyx price target raised to $17 from $14 at BTIG |
| January 8, 2026 9:34 pm | — | Piper Sandler | $16.00 | $7.00 | TheFly | Ardelyx upgraded to Overweight from Neutral at Piper Sandler |
| January 8, 2026 5:46 pm | Christopher Raymond | Raymond James | $19.00 | $7.00 | TheFly | Ardelyx price target raised to $19 from $16 at Raymond James |
| November 4, 2025 2:10 pm | — | Piper Sandler | $10.00 | $5.86 | TheFly | Ardelyx price target raised to $10 from $9 at Piper Sandler |
| August 5, 2025 1:39 pm | — | Wedbush | $14.00 | $5.13 | TheFly | Ardelyx price target raised to $14 from $13 at Wedbush |
| August 5, 2025 12:40 pm | — | UBS | $12.00 | $5.13 | TheFly | Ardelyx price target raised to $12 from $11 at Raymond James |
| March 4, 2025 11:53 am | — | BTIG | $14.00 | $5.41 | TheFly | Ardelyx initiated with a Buy at BTIG |
Latest News for ARDX
According to an SEC filing, an executive at Ardelyx reported selling 81,898 directly held Common Stock shares on June 18, 2026, generating a transaction value of $490,000. The sale represented 17.8% of Williams's direct Common Stock holdings, reducing her Common Stock position to 378,195 shares (direct) post-transaction.
Ardelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability.
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York.
Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside.
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and selected nutrition biomarkers at the National…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARDX.
U.S. House Trading
No House trades found for ARDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.